Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
|Earning Growth (QoQ)|
|Revenue Growth (QoQ)|
|Held by Institutions %||84%|
|1 Day Vol Adjusted Return||0.3|
|1 Month Vol Adjusted Return||1.9|
|3 Month Vol Adjusted Return||-6.0|
|6 Month Vol Adjusted Return||-6.0|
|20 Days SMA Price ZScore||0.6|
|50 Days SMA Price ZScore||0.0|
|12 -26 Days PPO||-0.4|
|1 Month Average Short Volume Ratio||47.9|
|1 Day Volume Change ZScore||0.1|
|1 Month Daily Vol||2.7|
Bluebird (BLUE) delivered earnings and revenue surprises of -0.66% and 19.44%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the first quarter ended March 31, 2021 and shared recent operational progress.
In this episode of Rule Breaker Investing, we review 5 Stocks for the Coronavirus, 5 Stocks for the Age of Miracles, and 5 Stocks I Own That You Should, Too. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. David Gardner: Last April, the market was in as dark a place as any of us have seen for more than 10 years -- the 35% loss of the S&P 500 in 32 days.
Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences:
Bristol Myers Squibb (NYSE: BMY) and bluebird bio (NASDAQ: BLUE) recently gained Food and Drug Administration approval of Abecma. In this video from Motley Fool Live, recorded on March 29, Fool.com Contributors Brian Orelli and Keith Speights discuss the prospects for Abecma and what the companies are doing to increase the potential market for the chimeric antigen receptor T-cell (CAR-T) product. Brian Orelli: On Friday, the FDA approved Bristol Myers Squibb and Bluebird Bio's CAR-T treatment ...
Last week, Vertex Pharmaceuticals (NASDAQ: VRTX) announced that it would pay CRISPR Therapeutics (NASDAQ: CRSP) a whopping $900 million to take more control of the duo's gene therapy collaboration, CTX001. CTX001 is being investigated as a potentially curative treatment for severe sickle cell disease and beta thalassemia, a rare blood disorder. Beti-cel is already on the market in the EU for beta thalassemia, but Bluebird is still facing a slew of problems in the U.S. and in major European mar...
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.